Settlement Docs Off-Limits In Rituxan Fraud Suit

Law360, New York (October 8, 2010, 1:58 PM EDT) -- A qui tam plaintiff accusing Genentech Inc. of defrauding Medicare through the promotion of off-label uses of its non-Hodgkin’s lymphoma drug Rituxan has lost a bid to extract details of failed settlement negotiations between the drugmaker and the federal government relating to identical claims.

Ruling on competing discovery requests Thursday, Judge Paul Diamond of the U.S. District Court for the Eastern District of Pennsylvania denied relator John Underwood’s motion to compel and granted Genentech’s motion for a protective order privileging correspondence between the company and the...
To view the full article, register now.